| Date | Title | Description |
| 18.08.2026 | Abcuro Raises $66M in Series D Funding | Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, raised $66M in Series D funding.
The round was led by New Leaf Ve... |
| 11.08.2026 | Epicrispr Biotechnologies Raises $90M in Series C Funding | Epicrispr Biotechnologies, a San Francisco, CA-based provider of a programmable epigenetic medicines platform, raised $90M in Series C financing.
The round was led by Octagon Capital and Janus Henderson Investors with participation from Fid... |
| 10.08.2026 | Expedition Therapeutics Closes $115 Million Series B |
SAN FRANCISCO, CA, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B f... |
| 09.08.2026 | Expedition Therapeutics Lands $115M Series B |
SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round.
>> Click here for more funding data on Expedition Therapeutics
>> To export Expedition Therapeutic... |
| 07.08.2026 | AI Revolutionizes Drug Trials: QuantHealth Secures $45M to Predict Success | QuantHealth raises $45M in Series B funding. Its AI platform simulates clinical trials. This drastically cuts drug development costs and failure rates. The technology boasts 90% predictive accuracy. It optimizes trial designs for major phar... |
| 05.08.2026 | Expedition Therapeutics Raises $115M in Series B Funding | Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing.
The round was led by General Atlantic with participation from RA Capital, Vivo Capital, Sofinnova Investments, Nov... |
| 04.08.2026 | QuantHealth Raises $45M to Let Pharm Test Clinical Trials with AI Before Spending Billions | Drug development is a gamble. More than 90% of drugs that enter clinical trials fail. Three out of four of those failures are because the drug didn’t work or wasn’t safe. And by the time you find out, you’ve already spent years and hundreds... |
| 04.08.2026 | Beyond Real-World Trial Iteration: QuantHealth Secures $45M for AI Clinical Simulation | What You Should Know
Tel Aviv-based AI clinical simulation platform QuantHealth closed a $45 million Series B financing round led by Qumra Capital.
The round saw participation from major strategic and venture investors, including Sanofi Ven... |
| 04.08.2026 | QuantHealth raises $45M Series B to use AI to predict how patients will respond to therapies | QuantHealth has raised $45 million in Series B funding to scale an ambitious idea: use AI to test clinical trials before drugmakers test them on patients. The round was led by Qumra Capital, with participation from Pitango HealthTech, Sanof... |
| 16.07.2026 | AdvanCell Closes $315 Million Series D |
BOSTON, MA, AdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of an oversubscribed and upsized $315 million Series D financing.
>> Click here for more funding data on AdvanCell
>> To export AdvanCel... |
| 15.07.2026 | AdvanCell Closes $315 Million Series D Financing To Advance Targeted Alpha Therapies | AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, announced the closing of an oversubscribed and upsized $315 million Series D financing. The round was led by Ally Bridge Group and co-le... |
| 15.07.2026 | AdvanCell Closes US $315M in Series D Funding | AdvanCell, a Boston, MA- and Brisbane, Australia-based clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, raised US $315M Series D in funding.
The round was led by Ally Bridge Group and Alpha Wave, al... |
| 14.07.2026 | Draig Therapeutics Raises $65 Million Series B To Advance Neuropsychiatric Therapies | Draig Therapeutics announced the closing of an oversubscribed $65 million Series B financing to accelerate development of its pipeline of neuropsychiatric therapies. The round was led by new investor Deep Track Capital, with participation f... |
| 14.07.2026 | Draig Therapeutics Closes $65 Million Series B To Advance AMPA And GABAA Receptor Modulators In Neuropsychiatric Disorders | Draig Therapeutics, a clinical-stage biopharmaceutical company co-founded by Cardiff University and SV Health Investors and headquartered across Newton, Massachusetts and Cardiff, United Kingdom, has closed an oversubscribed $65 million Ser... |
| 22.06.2026 | Nura Bio Raises $73.8M in Series B Funding | Nura Bio Inc., South San Francisco, CA-based clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, raised $73.8M in Series B funding.
The round was led by The Column Group, with participation from Euc... |
| 22.06.2026 | Bionyra Pharma Raises $165 Million Series A To Advance Biologics For Inflammatory Diseases | Bionyra Pharma announced its launch and an oversubscribed $165 million Series A financing round. The round was co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Heal... |
| 22.06.2026 | Bionyra Pharma Raises $165M in Series A Funding | Bionyra Pharma, a Paris, France- and Boston, MA-based clinical-stage biopharmaceutical company developing new biologics for immune-mediated inflammatory diseases, raised $165M in Series A funding.
The round was led by Jeito Capital and Sofi... |
| 21.06.2026 | Memento Medicines Raises $93 Million Series A For Retinal Disease Therapy | Memento Medicines announced the completion of a $93 million Series A financing round to advance MMT-205, its lead biologic therapy for retinal diseases. The round was co-led by Forbion, RA Capital Management, and Avego BioScience Capital, w... |
| 19.06.2026 | Memento Medicines Raises $93M in Series A Funding | Memento Medicines, Inc., a Boston, MA-based biotech company developing biologic therapies for retinal diseases, raised $93M in Series A funding.
The round was led by Forbion, RA Capital Management and Avego BioScience Capital, with particip... |
| 14.05.2026 | BranchLab Secures $26M Series A: AI Transforms Pharma Commercialization | BranchLab finalized a $26 million Series A funding round. McKesson Ventures led the investment, boosting total funding to $35 million. This capital propels BranchLab’s advanced AI platform. It revolutionizes pharmaceutical commercialization... |
| 13.05.2026 | BranchLab Raises $26M in Series A Funding | BranchLab, a Boulder, CO-based provider of an AI platform supporting healthcare commercialization, raised $26M in Series A funding.
The round was led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and A... |
| 13.05.2026 | BranchLab: $26 Million Series A Raised To Expand AI Platform For Pharma Commercialization | BranchLab announced a $26 million Series A financing round led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. The financing brings the company’s total funding to $35 million.
The compa... |
| 06.05.2026 | Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology Pipeline | Windward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, S... |
| 05.05.2026 | Windward Bio secures USD 165 million to advance clinical trials |
WIN378, Windward's lead program, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression ... |
| 21.02.2026 | Korsana Biosciences Launches With $175 Million To Advance Alzheimer’s Therapeutics | Korsana Biosciences, a biotechnology company focused on discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, announced its emergence from stealth with $175 million in funding from a syndicate of hea... |
| 18.02.2026 | Korsana Biosciences Raises $175M in Funding | Korsana Biosciences, a Waltham, MA-based biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, raised $175M in total funding.
The amount consisted of a $25M Seed investment from... |
| 11.01.2026 | Diagonal Therapeutics Secures $125M to Propel Innovative Antibody Therapies | Diagonal Therapeutics secured $125M Series B funding. This advances DIAG723, a first-in-class clustering antibody. It targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). The Watertown biotech corre... |
| 11.01.2026 | Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the Clinic | Diagonal Therapeutics announced it has raised $125 million in an oversubscribed Series B financing to advance its lead program, DIAG723, a first-in-class “clustering antibody” designed to correct dysregulated receptor signaling implicated i... |
| 09.01.2026 | Diagonal Therapeutics Raises $125M in Series B Financing | Diagonal Therapeutics, a Watertown, MA-based biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, raised $125M in Series B Funding.
The round was co-led by ... |
| 15.12.2025 | ial Library Secures $10M to Democratize Clinical Trial Access | Trial Library, a San Francisco-based AI platform, just raised $10 million in Series A funding. This investment aims to expand access to clinical trials *outside* major research hospitals. The company focuses on community-based care. It uses... |
| 10.12.2025 | Trial Library: $10 Million Raised To Expand Access To Community-Based Clinical Trials | Trial Library has secured $10 million in Series A funding to accelerate its efforts to expand access to clinical trials within community healthcare settings. The round was co-led by Next Ventures and SemperVirens Venture Capital, with parti... |
| 18.11.2025 | T-Therapeutics Secures $91 Million to Advance Bispecific Therapies | T-Therapeutics boosts Series A to $91M. New funds will push cancer, autoimmune bispecifics to trials. OpTiMus platform aims to unlock undruggable targets. Investors show strong confidence.
**T-Therapeutics Secures $91 Million to Advance Bis... |
| 14.11.2025 | T-Therapeutics: Series A Extended To $91 Million As It Advances First-In-Class Bispecifics Toward The Clinic | T-Therapeutics has expanded its Series A financing to a total of $91 million after securing an additional $32 million from new and existing investors. The Cambridge-based biotechnology company, which develops next-generation T cell receptor... |
| 13.11.2025 | Cambridge startup T-Therapeutics secures €27.5 million to improve how the immune system targets disease | T-Therapeutics, a British BioTech company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announced the successful expansion of its Series A financing, raising a further €27.5 million (... |
| 12.10.2025 | Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders | Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ... |
| 10.10.2025 | Expedition Therapeutics Raises $165M in Funding | Expedition Therapeutics, a San Francisco, CA-based biotech company developing therapies for novel inflammatory and respiratory diseases, raised $165M in Series A financing.
The round was led by Sofinnova Investments and Novo Holdings, with ... |
| 09.10.2025 | Expedition Therapeutics: $165 Million Series A Raised For Advancing DPP1 Inhibitor For COPD | Expedition Therapeutics, a biotechnology company dedicated to developing therapies for novel inflammatory and respiratory diseases, has closed an oversubscribed and upsized Series A financing round, raising $165 million. This financing roun... |
| 09.10.2025 | Expedition resupplies for phase 2 COPD voyage with $165M series A | Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstruct... |
| 01.10.2025 | Star Therapeutics Raises $125M in Series D Financing | Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding.
The round was co-led by Sanofi Ventures and Vi... |
| 29.09.2025 | Sanofi: $625 Million Commitment Announced To Advance Investments In Biotech | Sanofi Ventures, the dedicated corporate venture capital arm of the global biopharmaceutical company Sanofi, has announced a significant expansion of its investment capacity. The company has committed an additional $625 million over multipl... |
| 18.09.2025 | Character Biosciences Expands Series B Extension | Character Biosciences, Jersey City, NJ-based precision medicine company, raised an undisclosed amount in Series B extension.
Backers included Sanofi Ventures.
The company intends to use the funds to further advance the clinical development ... |
| 14.09.2025 | Odyssey Therapeutics: $213 Million Series D Closed For Advancing Autoimmune Disease Pipeline | Odyssey Therapeutics, a clinical-stage biopharmaceutical company, has closed an oversubscribed $213 million Series D financing to accelerate the development of its portfolio of medicines targeting autoimmune and inflammatory diseases. The r... |
| 25.04.2025 | Granite Bio debuts with $100 million to tackle autoimmune diseases |
Granite Bio is a biotechnology company developing first-in-class antibodies that target the root causes of a variety of inflammatory, autoimmune and fibrotic conditions. Its pipeline comprises two lead candidates. GRT-001 depletes pro-infl... |
| 10.02.2025 | AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing | Sydney, Australia – 3 February 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This ... |
| 11.01.2023 | Sanofi Ventures Announces Multi-Year Capital Commitment from Sanofi; Evergreen Fund Increases to $750M | Sanofi Ventures has announced an additional multi-year commitment from Sanofi (EURONEXT: SAN and NASDAQ: SNY), with an increase in capital to more than $750m to the evergreen venture fund.
In addition to serving as a financial partner to to... |
| 14.12.2017 | NEA-backed Curisium Raises $3.5M Seed | Curisium, a healthcare technology and services company that enables innovative contracting at scale via its blockchain-based platform, announced today it has raised $3.5M in seed financing from Flare Capital Partners, New Enterprise Associa... |
| 14.12.2017 | Flare-backed Curisium Raises $3.5M Seed | Curisium, a healthcare technology and services company that enables innovative contracting at scale via its blockchain-based platform, announced today it has raised $3.5M in seed financing from Flare Capital Partners, New Enterprise Associa... |
